Logo image of CYAD.BR

CELYAD ONCOLOGY (CYAD.BR) Stock Fundamental Analysis

EBR:CYAD - Euronext Brussels - BE0974260896 - Common Stock - Currency: EUR

0.551  -0.03 (-5%)

Fundamental Rating

2

Overall CYAD gets a fundamental rating of 2 out of 10. We evaluated CYAD against 69 industry peers in the Biotechnology industry. CYAD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYAD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYAD has reported negative net income.
CYAD had a negative operating cash flow in the past year.
CYAD had negative earnings in each of the past 5 years.
CYAD had a negative operating cash flow in each of the past 5 years.
CYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFCYAD.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

CYAD has a Return On Assets (-51.89%) which is comparable to the rest of the industry.
CYAD has a Return On Equity of -134.01%. This is in the lower half of the industry: CYAD underperforms 60.87% of its industry peers.
Industry RankSector Rank
ROA -51.89%
ROE -134.01%
ROIC N/A
ROA(3y)-97.56%
ROA(5y)-70.12%
ROE(3y)-381%
ROE(5y)-252.25%
ROIC(3y)N/A
ROIC(5y)N/A
CYAD.BR Yearly ROA, ROE, ROICCYAD.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

CYAD has a Gross Margin (32.35%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of CYAD has declined.
The Profit Margin and Operating Margin are not available for CYAD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.35%
GM growth 5Y-20.2%
CYAD.BR Yearly Profit, Operating, Gross MarginsCYAD.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200K -400K -600K -800K

More info and screens

4

2. Health

2.1 Basic Checks

CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYAD has more shares outstanding than it did 1 year ago.
CYAD has more shares outstanding than it did 5 years ago.
CYAD has a worse debt/assets ratio than last year.
CYAD.BR Yearly Shares OutstandingCYAD.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CYAD.BR Yearly Total Debt VS Total AssetsCYAD.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.61, we must say that CYAD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.61, CYAD is in line with its industry, outperforming 40.58% of the companies in the same industry.
A Debt/Equity ratio of 0.14 indicates that CYAD is not too dependend on debt financing.
The Debt to Equity ratio of CYAD (0.14) is better than 68.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -2.61
ROIC/WACCN/A
WACC7.6%
CYAD.BR Yearly LT Debt VS Equity VS FCFCYAD.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

CYAD has a Current Ratio of 3.79. This indicates that CYAD is financially healthy and has no problem in meeting its short term obligations.
CYAD has a Current ratio of 3.79. This is in the better half of the industry: CYAD outperforms 75.36% of its industry peers.
CYAD has a Quick Ratio of 3.79. This indicates that CYAD is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.79, CYAD is doing good in the industry, outperforming 75.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.79
Quick Ratio 3.79
CYAD.BR Yearly Current Assets VS Current LiabilitesCYAD.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.53% over the past year.
The Revenue has grown by 63.64% in the past year. This is a very strong growth!
The Revenue for CYAD have been decreasing by -49.53% on average. This is quite bad
EPS 1Y (TTM)82.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.59%
Revenue 1Y (TTM)63.64%
Revenue growth 3Y173.24%
Revenue growth 5Y-49.53%
Sales Q2Q%-68.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYAD.BR Yearly Revenue VS EstimatesCYAD.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
CYAD.BR Yearly EPS VS EstimatesCYAD.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYAD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYAD.BR Price Earnings VS Forward Price EarningsCYAD.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYAD.BR Per share dataCYAD.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CYAD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELYAD ONCOLOGY

EBR:CYAD (3/26/2025, 5:29:56 PM)

0.551

-0.03 (-5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07
Earnings (Next)04-02 2025-04-02/amc
Inst Owners55.35%
Inst Owner ChangeN/A
Ins Owners0.51%
Ins Owner ChangeN/A
Market Cap12.45M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 122.05
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 2.11
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.28
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.89%
ROE -134.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.35%
FCFM N/A
ROA(3y)-97.56%
ROA(5y)-70.12%
ROE(3y)-381%
ROE(5y)-252.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.35%
GM growth 5Y-20.2%
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.63%
Cap/Sales 915.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.79
Quick Ratio 3.79
Altman-Z -2.61
F-Score3
WACC7.6%
ROIC/WACCN/A
Cap/Depr(3y)50.68%
Cap/Depr(5y)40.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)63.64%
Revenue growth 3Y173.24%
Revenue growth 5Y-49.53%
Sales Q2Q%-68.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.73%
OCF growth 3YN/A
OCF growth 5YN/A